Valeritas Holdings Inc (VLRX) Files 10-K for the Fiscal Year Ended on December 31, 2017

GuruFocus.com
0

- By insider

Valeritas Holdings Inc (VLRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Valeritas Holdings Inc is a commercial-stage medical technology company. It is engaged in the business of improving health and simplifying life for diabetic patients by developing and commercializing innovative technologies. Valeritas Holdings Inc has a market cap of $21.300 million; its shares were traded at around $3.04 with and P/S ratio of 0.43.


For the last quarter Valeritas Holdings Inc reported a revenue of $5.78 million, compared with the revenue of $4.80 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $20.2 million, an increase of 3.6% from last year.

The reported loss per diluted share was $8.94 for the year, compared with the loss per share of $0 in the previous year. The Valeritas Holdings Inc had an operating margin of -223.6%, compared with the operating margin of -172.75% a year before. The 10-year historical median operating margin of Valeritas Holdings Inc is -261.61%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, Valeritas Holdings Inc has the cash and cash equivalents of $26.0 million, compared with $9.87 million in the previous year. The long term debt was $36.0 million, compared with $59.0 million in the previous year. The interest coverage to the debt is 8.4. Valeritas Holdings Inc has a financial strength rank of 3 (out of 10).

At the current stock price of $3.04, Valeritas Holdings Inc is traded at 22.4% discount to its historical median P/S valuation band of $3.92. The P/S ratio of the stock is 0.43, while the historical median P/S ratio is 0.55. The stock lost 89.93% during the past 12 months.

For the complete 20-year historical financial data of VLRX, click here.

This article first appeared on GuruFocus.


Advertisement

Recommended Stories